[Replay] Jefferies Global Healthcare Conference 2025
November 13, 2025
November 13, 2025
Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth
November 11, 2025
November 11, 2025
Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark
November 10, 2025
November 10, 2025
Medincell to Participate in the UBS Global Healthcare Conference (Palm Beach) and the Stifel Healthcare Conference (New-York)
November 6, 2025
November 6, 2025
UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025
November 5, 2025
November 5, 2025
Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York)
October 22, 2025
October 22, 2025
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
October 10, 2025
October 10, 2025
Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®
September 23, 2025
September 23, 2025
New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®
September 22, 2025
September 22, 2025
New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed
September 22, 2025
September 22, 2025
Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
September 17, 2025
September 17, 2025
Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to the Board of Directors
September 12, 2025
September 12, 2025
Contacts
Medincell
David Heuzé
Head of Corporate and Financial Communications, and ESG
